William Blair analyst Andy Hsieh reiterated an Outperform rating on FibroGen (NASDAQ: FGEN) following Pamrevlumab’s promising activity in IPF ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE